Results 1 to 10 of about 60,500 (292)

Effects of Oral Doxofylline and Procaterol on Chronic Obstructive Pulmonary Disease: A Randomized Crossover Study [PDF]

Medical Sciences
Background: Oral bronchodilators may serve as an adjunctive therapy in patients with chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the effects of oral doxofylline and oral procaterol on lung function and clinical symptoms in ...
Narongkorn Saiphoklang, Sarawut Panichaporn, Thiravit Siriyothipun, Pitchayapa Ruchiwit   +3 more
doaj   +2 more sources

Bronchodilator responsiveness and reported respiratory symptoms in an adult population. [PDF]

PLoS ONE, 2013
The relationship between patient-reported symptoms and objective measures of lung function is poorly understood.To determine the association between responsiveness to bronchodilator and respiratory symptoms in random population samples.4669 people aged ...
Wan C Tan, Jean Bourbeau, Paul Hernandez, Kenneth R Chapman, Robert Cowie, J Mark FitzGerald, Shawn Aaron, Darcy D Marciniuk, Francois Maltais, A Sonia Buist, Denis E O'Donnell, Don D Sin, CanCOLD Collaborative Research Group   +12 more
doaj   +2 more sources

Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety

International Journal of COPD, 2022
Purpose Randomized trials report that single-inhaler triple therapy is more effective than dual bronchodilators at reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
S. Suissa, S. Dell'aniello, P. Ernst
semanticscholar   +1 more source

Pharmacoepidemiology of Drug Exposure in Intubated and Non-Intubated Preterm Infants With Severe Bronchopulmonary Dysplasia

Frontiers in Pharmacology, 2021
Background: Infants with severe bronchopulmonary dysplasia (BPD) are commonly treated with off-label drugs due to lack of approved therapies. To prioritize drugs for rigorous efficacy and safety testing, it is important to describe exposure patterns in ...
T. Lewis, W. Truog, L. Nelin, N. Napolitano, R. L. McKinney, and on behalf of The BPD Collaborative   +5 more
doaj   +1 more source

Cucumis sativus L. Seeds Ameliorate Muscular Spasm-Induced Gastrointestinal and Respiratory Disorders by Simultaneously Inhibiting Calcium Mediated Signaling Pathway

Pharmaceuticals, 2021
Cucumis sativus L. is globally cultivated as an edible vegetable. Besides its nutritional benefits, it is used in traditional medicines against various ailments. The current study was designed to elucidate the multi-target mechanisms of a C.
Muqeet Wahid, Fatima Saqib, Hanadi Talal Ahmedah, Claudia Mihaela Gavris, Vincenzo De Feo, Mircea Hogea, Marius Moga, Radu Chicea   +7 more
doaj   +1 more source

Managing bronchiolitis in pediatric patients: Current evidence

Indian Journal of Respiratory Care, 2022
Background: Acute bronchiolitis is an inflammatory process affecting small airways. Although most cases are self-limiting, it is still one of the most common causes of hospitalization below 24 months of age. Treatment is mainly supportive. The purpose of
Subhranshu Sekhar Dhal, Hiremath Sagar
doaj   +1 more source

Anti-Bronchospasmodic Effect of JME-173, a Novel Mexiletine Analog Endowed With Highly Attenuated Anesthetic Activity

Frontiers in Pharmacology, 2020
Local anesthetics (LAs), such as lidocaine and mexiletine, inhibit bronchoconstriction in asthmatics, but adverse effects limit their use for this specific clinical application.
Katharinne Ingrid Moraes Carvalho, Diego de Sá Coutinho, Humberto Cavalcante Joca, Artur Santos Miranda, Jader dos Santos Cruz, Emerson Teixeira Silva, Marcus Vinícius Nora Souza, Robson Xavier Faria, Patricia Machado Rodrigues e Silva, Jorge Carlos Santos Costa, Marco Aurélio Martins   +10 more
doaj   +1 more source

Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease [PDF]

Journal of Clinical and Diagnostic Research, 2021
Trelegy Ellipta (GlaxoSmithKlineTM) is the first single inhaler triple combination therapy comprising of umeclidinium, vilanterol and fluticasone approved by the United States Food and Drug Administration (US FDA) for patients with severe COPD in 2019.
B Jagan Nathan, Melina I Sahay, AK Gautham, DK Sriram, Melvin George   +4 more
doaj   +1 more source

Economic Evaluation of an Asthma Therapy: Effect of Salmeterol on Loss of Labor Productivity in Japan

Allergology International, 2005
Background: Asthma can have a negative impact on the productivity of paid and unpaid individuals. In this study, we aimed to investigate the impact of salmeterol, which, in recent years, has become available for the treatment of asthma in Japan, on the ...
Takehiko Miyagawa, Shuzo Nishimura
doaj   +1 more source

Bronchodilatory and B-adrenergic effects of methanolic and aqueous extracts of Althaea root on isolated tracheobronchial smooth rat muscle

Advanced Biomedical Research, 2015
Background: The smooth muscle contractions of the tracheobronchial airways are mediated through the balance of adrenergic, cholinergic and peptidergic nervous mechanisms.
Behrang Alani, Mohammad Zare, Mahdi Noureddini   +2 more
doaj   +1 more source